This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Young Women's Breast Cancer Study (HOHO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01468246
Recruitment Status : Active, not recruiting
First Posted : November 9, 2011
Last Update Posted : April 3, 2023
Sponsor:
Information provided by (Responsible Party):
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer.

Condition or disease
Breast Cancer

Detailed Description:
This is a longitudinal cohort study of young women with breast cancer. Over a 6-year period, the investigators aim to identify over 1,600 women age 40 and younger with newly diagnosed breast cancer from academic and community health care institutions. It is anticipated that 1,300 of these women will agree to participate in an observational study. Patient surveys, medical record review, and blood and tissue collection will be utilized. Women will be surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of 10 year following diagnosis). The study will investigate short and long-term disease and treatment issues, and psychosocial concerns at baseline and in follow-up among a cohort of young women (age 40 or younger) newly diagnosed with breast cancer. The investigators aim to characterize the population of young women at diagnosis and in follow-up regarding disease and psychosocial outcomes (e.g., presentation and disease characteristics, treatment patterns and quality of care, short and long-term side effects, and psychosocial concerns including fertility, sexual functioning, and menopausal issues). The investigators will also collect tumor and blood specimens to characterize the tumors, and bank for future studies including molecular evaluations of disease characteristics, genetic variability and hormonal levels in blood. Ultimately, the investigators aim to develop predictors of outcome, and identify areas that may be amenable to intervention.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1302 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study
Study Start Date : November 2006
Estimated Primary Completion Date : November 2025
Estimated Study Completion Date : January 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Young Women
Young women with newly diagnosed breast cancer


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Identify a cohort of young women (age 40 or younger) newly diagnosed with breast cancer [ Time Frame: 10 years ]
    Characterize the population of young women at diagnosis and in follow-up regarding disease and psychosocial outcomes (e.g., presentation and disease characteristics including evaluating women with metastatic disease, reported frequency and factors associated with genetic testing, treatment patterns and quality of care, short and long-term side effects, and psychosocial concerns including fertility, sexual functioning, and menopausal issues).

  2. Specimen Collection [ Time Frame: 10 years ]
    Collect tumor and blood specimens to characterize the tumors, and bank for future studies including molecular evaluations of disease characteristics, genetic variability and hormonal levels in blood.


Secondary Outcome Measures :
  1. Identify Predictors of Outcome [ Time Frame: 10 years ]
    Ultimately, the investigators aim to develop predictors of outcome and identify areas that may be amenable to intervention for young women with breast cancer.


Biospecimen Retention:   Samples With DNA
The investigators are collecting blood and tumor specimens.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study includes women who are newly-diagnosed with breast cancer. They must be 40 or younger at their diagnosis.
Criteria

Inclusion Criteria:

  • Female
  • Diagnosis of breast cancer
  • Age 40 or younger at diagnosis
  • Informed consent obtained from patient
  • Ability to understand written and spoken English to the extent necessary to complete the questionnaires

Exclusion Criteria:

  • Inability to understand written and spoken English to the extent necessary to complete the questionnaires
  • Absence of informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01468246


Locations
Layout table for location information
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Massachusetts
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Massachusetts General Hospital
Boston, Massachusetts, United States, 02215
MGH/North Shore Cancer Center
Danvers, Massachusetts, United States, 01923
Cape Cod Hospital
Hyannis, Massachusetts, United States, 02601
Lowell General Hospital
Lowell, Massachusetts, United States, 01854
DF/BWCC at Milford Regional Medical Center
Milford, Massachusetts, United States, 01757
Newton-Wellesley Hospital
Newton, Massachusetts, United States, 02462
South Shore Hospital
South Weymouth, Massachusetts, United States, 02190
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Hampshire
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, United States, 03053
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, 3M5
Sponsors and Collaborators
Dana-Farber Cancer Institute
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey Peppercorn, MD Massachusetts General Hospital
Principal Investigator: Steven Come, MD, MPH Beth Israel Deaconess Medical Center
Principal Investigator: Therese Mulvey, MD Mass General/North-Shore Cancer Center
Principal Investigator: Blair Ardman, MD Lowell General Hospital
Principal Investigator: Lawrence Blaszkowsky, MD Newton-Wellesley Hospital
Principal Investigator: Frank G Basile, MD Cape Cod Hospital
Principal Investigator: Ellen Warner, MD Sunnybrook Health Sciences Centre
Principal Investigator: Virginia Borges, MD University of Colorado, Denver
Principal Investigator: Kathryn Ruddy, MD, MPH Mayo Clinic
Principal Investigator: Katherina Zabicki Calvillo, MD, FACS South Shore Hospital
Principal Investigator: Jeanna Walsh, MD Dana-Farber/New Hampshire Oncology-Hematology
Principal Investigator: Natalie Sinclair, MD DF/BWCC at Milford Regional Medical Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Ann H. Partridge, MD, MPH, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01468246    
Other Study ID Numbers: 06-169
First Posted: November 9, 2011    Key Record Dates
Last Update Posted: April 3, 2023
Last Verified: March 2023
Keywords provided by Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute:
Breast Cancer
Cohort
Young Women
Survivorship
Fertility
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases